dapiglutide
dapiglutide (VK2735) is Viking Therapeutics' dual GLP-1/GIP receptor agonist in development for weight management in adults with obesity. The drug mimics two gut hormones — GLP-1 and GIP — that regulate appetite and blood sugar, prompting the brain to reduce food intake and the body to use energy more efficiently. Viking is evaluating both a once-weekly subcutaneous injection and a daily oral formulation, targeting a competitive profile against semaglutide and tirzepatide in the Phase 3 VENTURE trial.
Upcoming catalysts
Programs
Obesity
Obesity affects over 40% of US adults and is a primary driver of type 2 diabetes, cardiovascular disease, and several cancers; existing GLP-1 agonists (semaglutide, tirzepatide) produce 15–21% mean body-weight loss at 68–72 weeks. The Phase 3 VENTURE trial tests dapiglutide's dual GLP-1/GIP mechanism in adults with obesity or overweight plus a comorbidity, comparing weight reduction, GI tolerability, and discontinuation rate against the established class benchmark.